We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

114 hedge funds and large institutions have $209M invested in Cymabay Therapeutics in 2020 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 31 increasing their positions, 34 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more capital invested

Capital invested by funds: $88.7M → $209M (+$120M)

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

23% more call options, than puts

Call options by funds: $2.07M | Put options by funds: $1.69M

12% more funds holding

Funds holding: 102 → 114 (+12)

9% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 34

Holders
114
Holders Change
+12
Holders Change %
+11.76%
% of All Funds
2.34%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.08%
New
36
Increased
31
Reduced
34
Closed
24
Calls
$2.07M
Puts
$1.69M
Net Calls
+$384K
Net Calls Change
-$571K

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$8.21M
2
SCM
Sio Capital Management
New York
+$6.25M
3
FCMI
Foresite Capital Management III
California
+$4.62M
4
BBA
Baker Bros. Advisors
New York
+$4.39M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.99M

Top Sellers

Rank Fund Capital Flow
1
ECM
Engine Capital Management
New York
-$12.9M
2
Deutsche Bank
Deutsche Bank
Germany
-$8.01M
3
RG
Redmile Group
California
-$3.11M
4
IC
Ikarian Capital
Texas
-$2.42M
5
JP Morgan Chase
JP Morgan Chase
New York
-$2.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
101
Royal Bank of Canada
Ontario, Canada
$8K -$33.6K -11,659 -83%
First Manhattan
102
First Manhattan
New York
$8K +$7.21K +2,500 New
Nisa Investment Advisors
103
Nisa Investment Advisors
Missouri
$5K +$4.04K +1,400 New
GRP
104
Global Retirement Partners
California
$4K +$3.46K +1,200 New
Federated Hermes
105
Federated Hermes
Pennsylvania
$2K -$359K -124,522 -100%
CG
106
Cutler Group
California
$2K -$1.44K -500 -45%
PNC Financial Services Group
107
PNC Financial Services Group
Pennsylvania
$2K – – –
APA
108
American Portfolios Advisors
New York
$1.22K – – –
Daiwa Securities Group
109
Daiwa Securities Group
Japan
$1K – – –
SF
110
Synovus Financial
Georgia
$1K – – –
GWS
111
Glassman Wealth Services
Virginia
$1K +$678 +235 New
TC
112
Truvestments Capital
Florida
$1K +$921 +319 New
Franklin Resources
113
Franklin Resources
California
– -$1.7M -1,151,356 Closed
ACM
114
Asymmetry Capital Management
California
– -$1.13M -762,219 Closed
Acadian Asset Management
115
Acadian Asset Management
Massachusetts
– -$906K -611,297 Closed
MWNA
116
Marshall Wace North America
New York
– -$541K -365,866 Closed
2L
117
22NW LP
Washington
– -$438K -295,676 Closed
Swiss National Bank
118
Swiss National Bank
Switzerland
– -$175K -118,400 Closed
UBS AM
119
UBS AM
Illinois
– -$162K -109,476 Closed
KPF
120
K2 Principal Fund
Ontario, Canada
– -$123K -83,099 Closed
AS
121
Altshuler Shaham
Israel
– -$98K -66,400 Closed
SEI Investments
122
SEI Investments
Pennsylvania
– -$93K -62,875 Closed
SIM
123
Spark Investment Management
New York
– -$76K -51,992 Closed
Voloridge Investment Management
124
Voloridge Investment Management
Florida
– -$51K -34,525 Closed
PAM
125
Panagora Asset Management
Massachusetts
– -$33K -22,227 Closed
2 3 4
5
6

CBAY Hedge Fund Activity: Q2 2020 in Review

114 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2020, worth a combined $209M — up 135% from $88.7M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new CBAY positions and 24 closed out — a net gain of 12 holders — while 31 added to existing stakes and 34 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $8.21M. The largest seller was Engine Capital Management, cutting an estimated $12.9M.

  • 114 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2020, up from 102 in Q1 2020.
  • Funds reported $209M of Cymabay Therapeutics stock for Q2 2020, up 135% quarter-over-quarter.
  • 36 funds opened new Cymabay Therapeutics positions in Q2 2020 and 24 closed out, a net change of +12 holders.
  • The largest Cymabay Therapeutics buyer in Q2 2020 was Foresite Capital Management IV, an estimated $8.21M added.
  • The largest Cymabay Therapeutics seller in Q2 2020 was Engine Capital Management, an estimated $12.9M sold.

Based on aggregated 13F filings for Q2 2020.